Equis ISSN 2398-2977

Naproxen

Contributor(s): Adam Auckburally, Ruth Morgan

Introduction

Name

  • Naproxen.

Currently unavailable as a licensed veterinary product.

Class of drug

  • Non-steroidal anti-inflammatory drug.
  • Propionic acid.

Description

Chemical name

  • (+)-(S)-2-(6-methoxynaphthalen-2-yl)propionic acid.

Molecular formula

  • C14H14O3.

Molecular weight

  • 230.259 g.

Physical properties

  • White to off-white crystalline powder.
  • Available as 8 g packet containing 4 g naproxen or 2 g vial for reconstitution in 19 ml water to make 20 ml of a 10% solution for injection.

Storage requirements

  • Store at room temperature; avoid temperatures >40°C.
  • Protect from light.
  • Solution for injection must be used immediately following reconstitution - remainder should be discarded.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Not licensed in the UK.
  • Licensed for use in the US, but currently unavailable.
  • For the relief of inflammation and associated pain and lameness exhibited with myositis and other soft tissue diseases of the musculoskeletal system.
  • Not for use in horses intended for human consumption.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Do not administer with other NSAIDs or corticosteroids Therapeutics: anti-inflammatory drugs.
  • May compete for protein binding sites, leading to increased plasma concentrations of free drug and toxic effects. Reported examples of highly protein bound drugs which may be displaced by NSAIDs are oral anticoagulants, glucocorticoids, sulfonamides Therapeutics: sulfonamides, methotrexate Methotrexate, valproic acid and phenytoin Phenytoin.
  • Concurrent administration of other nephrotoxic drugs should be avoided.
  • Avoid co-administration with anticoagulant drugs.
  • May reduce the effects of furosemide   Furosemide  .

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Cagnardi P, Gallo M & Zonca A (2011) Pharmacokinetics and effects of alkalization during oral and intravenous administration of naproxen in horses. J Eq Vet Sci  31 (8), 456-462
  • Pasargiklian M & Bianco S (1986) Perspectives in the treatment of reversible airway obstruction. Respiration 50 (2), 131-136.
  • Tobin T (1979) Pharmacology review: the nonsteroidal anti-inflammatory drugs II. Equiproxen, meclofenamic acid, flunixin meglumine and others. J Eq Med Surg 6, 298-302.
  • Jones E W & Hamm D (1978) Comparative efficacy of phenylbutazone and naproxen in induced equine myositis. J Eq Med Surg 2, 341-347.

Other sources of information

  • Plumb D C (2011) Veterinary Drug Handbook. 7th edn. Wiley-Blackwell, USA.
  • Hanson P D & Maddison J E (2008) Nonsteroidal Anti-inflammatory Drugs and Chondroprotective Agents. In: Small Animal Clinical Pharmacology. 2nd edn. Eds: Maddison J E, Page S W & Church D B. Saunders Elsevier, USA. pp 287-309.
  • Kollias-Baker C & Cox K (2004) Non-steroidal Anti-inflammatory Drugs. In: Equine Clinical Pharmacology. Eds: Bertone J J & Horspool L J I. Saunders Elsevier, USA. pp 247-266.
  • Equiproxen® online information.

ADDED